MDC-735
/ Cellis
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 26, 2025
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
(AACR 2025)
- "The ability of MDC-735 to alter the tumor microenvironment and induce immune resistance to recurrence highlights its potential as a game-changing therapy. This innovative therapy promises to transform the landscape of platinum-resistant ovarian cancer treatment, providing a scalable and effective solution for a disease with limited options."
Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor
March 26, 2025
Macrophage-ferritin-drug conjugates: a novel approach to overcome glioblastoma drug resistance and induce long-term tumor immunity
(AACR 2025)
- "MDC-735 also outperformed current standard treatments such as temozolomide, radiation, and second-line agents like lomustine, which fail to achieve long-term survival. These findings highlight MDC-735 as a promising immunotherapeutic strategy for GBM, capable of targeting drug-resistant cancer cells, modulating the tumor microenvironment, and inducing durable anti-tumor immunity. Importantly, MDC-735 is designed as an allogeneic, off-the-shelf cell-based therapy, enabling scalable and timely delivery for clinical applications, addressing a significant unmet medical need in glioblastoma treatment."
IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
March 26, 2025
Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors
(AACR 2025)
- "MDC-735 demonstrated remarkable efficacy across diverse cancer models, including pancreatic cancer (BxPC3), ovarian cancer (SK-OV-3), breast cancer lung metastases (EMT6), bladder cancer (MB49), and head and neck cancer (SCC7)...Significantly, MDCs were prepared as off-the-shelf products, maintaining their activity upon thawing, highlighting their potential for clinical translation. This MDC platform represents a breakthrough in solid tumor therapy, offering a targeted, scalable, and effective treatment approach with broad applicability across multiple cancer types."
Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Head and Neck Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1